[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.161.130.145. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Evidence-Based Dermatology: Research Commentary
March 2007

What Are the Risks of Serious Infections and Malignancies for Patients Treated With Anti-Tumor Necrosis Factor Antibodies?

Arch Dermatol. 2007;143(3):405-406. doi:10.1001/archderm.143.3.405

Commentary on: Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. JAMA. 2006;295:2275-2285

Question: In patients with rheumatoid arthritis treated with infliximab or adalimumab, what is the risk of serious infection or malignancy compared with patients with rheumatoid arthritis who do not receive either anti–tumor necrosis factor (TNF) antibody?

First Page Preview View Large
First page PDF preview
First page PDF preview
×